Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: J Subst Abuse Treat. 2010 Oct 8;40(1):77–86. doi: 10.1016/j.jsat.2010.08.010

Table 2.

Cotinine-confirmed 7-day point prevalence abstinence [n (%)] by treatment group

Week Bupropion SR + CM (n = 37) Bupropion SR + Non-CM (n = 36) Placebo + CM (n = 29) Placebo + Non-CM (n = 32)
3 14 (37.8) 7 (19.4) 3 (10.3) 3 (9.4)
4 14 (37.8) 6 (16.7) 3 (10.3) 5 (15.6)
5 11 (29.7) 5 (13.9) 3 (10.3) 3 (9.4)
6 (End of Treatment) 10 (27.0) 3 (8.3) 3 (10.3) 3 (9.4)
12 (Follow-Up) 4 (10.8) 2 (5.6) 0 (0.0) 2 (6.3)

following initial 2-week grace period